Exclusive
Rick Claypool on Pay to Play Corporate Crime Enforcement Rick Claypool on Pay to Play Corporate Crime Enforcement Labaton Launches Whistleblower Practice with Former SEC Acting Chair Allison Herren Lee Labaton Launches Whistleblower Practice with Former SEC Acting Chair Allison Herren Lee Kremlin payment firm A7 has been pumping billions in ‘untraceable’ cash into global financial system Kremlin payment firm A7 has been pumping billions in ‘untraceable’ cash into global financial system
Current Affairs

Insilico teams up with US firm to build AI models predicting disease decades ahead

Hong Kong-listed artificial intelligence drug-discovery company Insilico Medicine has struck a collaboration with US-headquartered Human Longevity to co-develop what they describe as “the industry’s first…

By Samantha Johnson / May 27, 2026
Hong Kong-listed artificial intelligence drug-discovery company Insilico Medicine has struck a collaboration with US-headquartered Human Longevity to co-develop what they describe as “the industry’s first large-scale” AI foundation models capable of predicting diseases – such as cancer – decades before clinical symptoms appear.

The partnership was announced as the global longevity market, fuelled by an ageing population and rising consumption demand, was valued at about US$5.3 trillion and projected to reach US$8 trillion by 2030, according to a recent UBS report.

Insilico founder and CEO Alex Zhavoronkov, in a written reply, framed the tie-up as the world’s two leading companies in the AI and longevity fields joining forces, adding they “have developed a conceptually new type of personal longevity AI that will not only let you live longer, but also help you and others discover new longevity drugs that work for everyone.”

Advertisement

Neither party disclosed the exact investment amount. They described the arrangement as “a multimillion-dollar AI co-development collaboration”.

Shares of Insilico declined 4.21 per cent to HK$48.28 apiece on Tuesday. The company raised HK$2.28 billion (US$291 million) in its initial public offering in December. Its self-developed AI platform spans the entire drug discovery process, from identifying disease targets to designing drug candidates and predicting clinical outcomes.

Insilico CEO Alex Zhavoronkov frames the tie-up as the world’s two leading companies in the AI and longevity fields joining forces. Photo: Handout
Insilico CEO Alex Zhavoronkov frames the tie-up as the world’s two leading companies in the AI and longevity fields joining forces. Photo: Handout

The collaboration will be executed through Human Life Foundation Models (HLFM), a newly launched company set up by Human Longevity.

Advertisement

Don't Miss: